Parexel International to go private after $5 billion deal
The global biopharmaceutical service provider, Parexel, is being snapped up by private equity group Pamplona Capital Management in a deal valued at approximately $5 billion (including debt) marking further consolidation of the contract research sector. The groups have signed a definitive agreement under which Pamplona will acquire all of the outstanding shares of Paraxel for